WallStreetZenWallStreetZen

NASDAQ: DNLI
Denali Therapeutics Inc Earnings & Revenue

DNLI past revenue growth

How has DNLI's revenue growth performed historically?
Company
191.13%
Industry
89.94%
Market
19.39%
DNLI's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
DNLI's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
DNLI's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

DNLI earnings and revenue history

Current Revenue
$295.4M
Current Earnings
-$137.2M
Current Profit Margin
-46.5%

DNLI Return on Equity

Current Company
-11.5%
Current Industry
16.8%
Current Market
28.2%
DNLI's Return on Equity (-11.5%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when DNLI announces earnings.

DNLI Return on Assets

Current Company
-10.4%
Current Industry
3.2%
DNLI is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

DNLI Return on Capital Employed

Current Company
-9.16%
Current Industry
-42.4%
DNLI's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

DNLI vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
DNLI$295.39M-$128.37M-$137.25M+17.35%N/A
ACLX$131.66M-$22.77M-$50.54M+635.05%N/A
MRUS$38.34M-$156.86M-$149.65M+1.10%N/A
XENE$0.00-$184.98M-$188.60M-100.00%N/A
IDYA$15.50M-$124.76M-$128.89M-74.96%N/A

DNLI earnings dates

Next earnings date
Aug 6, 2024

Denali Therapeutics Earnings & Revenue FAQ

What were DNLI's earnings last quarter?

On Invalid Date, Denali Therapeutics (NASDAQ: DNLI) reported Q1 2024 earnings per share (EPS) of -$0.68, up 15% year over year. Total Denali Therapeutics earnings for the quarter were -$101.80 million. In the same quarter last year, Denali Therapeutics's earnings per share (EPS) was -$0.80.

If you're new to stock investing, here's how to buy Denali Therapeutics stock.

What was DNLI's earnings growth in the past year?

As of Q3 2024, Denali Therapeutics's earnings has grown year over year. Denali Therapeutics's earnings in the past year totalled -$137.25 million.

What is DNLI's earnings date?

Denali Therapeutics's earnings date is Invalid Date. Add DNLI to your watchlist to be reminded of DNLI's next earnings announcement.

What was DNLI's revenue last quarter?

On Invalid Date, Denali Therapeutics (NASDAQ: DNLI) reported Q1 2024 revenue of $0.00 up 100% year over year. In the same quarter last year, Denali Therapeutics's revenue was $35.14 million.

What was DNLI's revenue growth in the past year?

As of Q3 2024, Denali Therapeutics's revenue has grown 191.13% year over year. This is 101.19 percentage points higher than the US Biotechnology industry revenue growth rate of 89.94%. Denali Therapeutics's revenue in the past year totalled $295.39 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.